Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRAL-ANA: Anamorelin with chemoimmunotherapy in NSCLC with cancer cachexia
jRCT1071210053Completed
- Sponsor
- Clinical Research Support Center Kyushu
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anamorelin in non-small cell lung cancer (NSCLC) and cancer anorexia-cachexia syndrome (CACS), sponsored by Clinical Research Support Center Kyushu. Primary endpoint: Progression-free survival. Started Sep 2021; status: completed.
02
Drugs
anamorelin
03
Conditions
non-small cell lung cancer (NSCLC)cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on jRCT1071210053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071210053.